190 results on '"Crusoe, Edvan"'
Search Results
2. Impact of the lactate dehydrogenase in association with the International Staging System prognostic score in multiple myeloma patients treated in real life
3. CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil
4. Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira – 2022. Part I
5. POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis
6. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients
7. Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma
8. Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel – ABHH monoclonal gammopathies committe
9. Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
10. Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients
11. New proteasome inhibitors in the treatment of multiple myeloma
12. Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries
13. Challenges to achieving BMT in the treatment of AML in Brazil
14. Repositioning autologous stem cell transplantation in the management of newly diagnosed multiple myeloma
15. Multiple myeloma and central nervous system involvement: experience of a Brazilian center
16. Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries
17. COVID-19 in multiple myeloma patients: frequencies and risk factors for hospitalization, ventilatory support, intensive care admission and mortality –cooperative registry from the Grupo Brasileiro de Mieloma Multiplo (GBRAM)
18. Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients
19. P954: MULTIPLE MYELOMA IN LATIN AMERICA CANCER REGISTRY: THE MYLACRE STUDY
20. For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission
21. Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients
22. Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?
23. HSCT FOR MONOCLONAL GAMMOPATHIES: MULTIPLE MYELOMA AND AMYLOIDOSIS
24. Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study
25. Variability in End-of-Life Care and Perception of Palliative Care Among Physicians in the Hematology Unit of a Reference Service in the State of Bahia, Brazil
26. Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients: Response Rate Impacts on PFS
27. Outcomes of autologous transplantation for multiple myeloma according to different induction regimens
28. CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil
29. P-130: Brazilian ineligible multiple myeloma patients: real world data from a prospective multicenter platform
30. Impact of the lactate dehydrogenase in association with the International Staging System prognostic score in multiple myeloma patients treated in real life
31. MM-722 Lymphocyte Profiling in Newly Diagnosed Multiple Myeloma: First-Line Treatment with Cyclophosphamide Thalidomide, Dexamethasone, and Daratumumab
32. Lymphocyte Profiling in Newly Diagnosed Multiple Myeloma: First-Line Treatment with Cyclophosphamide, Thalidomide, Dexamethasone, and Daratumumab
33. The Brazilian association of hematology, hemotherapy, and cell therapy (ABHH) and its absolute commitment to ethics and absence of conflicts of interest
34. Monoclonal gammopathy of renal significance (MGRS): Real‐world data on outcomes and prognostic factors
35. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice
36. Progression Free Survival (PFS) Analysis of Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients
37. Evaluation of Hematopoietic Stem Cell Product As a New Site for Minimal Residual Disease By Next Generation Flow in Multiple Myeloma
38. COVID-19 in Multiple Myeloma Patients: Frequencies and Risk Factors for Hospitalization, Ventilatory Support, Intensive Care Admission and Mortality -Cooperative Registry from Grupo Brasileiro De Mieloma Multiplo (GBRAM)
39. P-172: Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: a quadruplet intensified treatment for transplant eligible newly diagnosed Multiple Myeloma (TE NDMM) patients final results
40. P-066: Effect of Daratumumab (DARA), Cyclophosphamide (C), T Halidomide (T) and Dexamethasone (D) combination of Lymphocyte populations of transplant eligible newly diagnosed Multiple Myeloma patients
41. P-173: Impact of Daratumumab (DARA) administration during transplant-eligible newly diagnosed Multiple Myeloma (TE NDMM) induction on stem cell (SC) mobilization count and post-transplant engraftment
42. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
43. Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma
44. Major Challenges for Palliative Care in Oncohematology: Analysis of the “Surprise Question” in a Reference Center
45. Real World Evidence- the Proportion of Myeloma Patients' Death Due to Early Progression
46. The Impact of Isatuximab Regimens on Hypogammaglobulinemia Occurrence, Recovery, and Associated Infections in Patients with Relapsed/Refractory Multiple Myeloma
47. Equity program: strategies on clinical studies as an aggregating potential
48. Parotid Large Cell Anaplastic Lymphoma ALK Negative: Case Report: AO-51
49. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
50. P-140 Multiple myeloma in Latin America cancer registry: the MYLACRE study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.